Genmab — Juni 2020

[E_L]

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) A/S on Tuesday, setting a price target of $40,

[E_L]

i actually thought they were already at $40

[Monforte]

@EL, you are right , see EL 11/6

[kkjoel]

They were. "He REITERATED a buy rating.." and apparently the same goes for the target (setting)...

[bikube]

ATH i U S 33,53 = 2229 Dkk

[E_L]

Seattle Genetics (SGEN) PT Raised to $210 at Oppenheimer on Positive Ph2 Tisotumab Vedotin (TV) Study

[Sukkeralf]

from what?

[E_L]

(from $200.00. They have 173.1M shares outstanding, so a $10 raise means $1.731bn in value

[bikube]

S Gen´s kurs i aftes 164,37

[E_L]

that would be almost dkk180 on Genmab? that seems a bit excessive?

[E_L]

@bikube yes, but that is not relevant in this calculation

[Mcjean]

Ok then Nordea will raise 15 kr. i think and DB and jyske will follow with a whopping 20 kr.

[E_L]

they valued it at 200 and raise it to 210; so they raise the value by $10 per share based on TV

[Mcjean]

Maybe im too optimistic!

[E_L]

we finally had nohope convinced of exponential growth and now you are starting
?!?!

[E_L]

Genmab, Seattle Genetics eye FDA filing for new cancer med after latest data drop https://www.fiercebiotech.com/biotech/genmab-seattle-genetics-eye-fda-filing-after-seeing-cancer-data

[E_L]

actually, guggenheim upgrades by 136dkk and BG by 150 so that calculation is in line really

[E_L]

Seattle Genetics, Genmab turn on TV for a highlight reel in cervical cancer — but a rival biotech promises a better show https://endpts.com/seattle-genetics-genmab-turn-on-tv-for-a-highlight-reel-in-cervical-cancer-but-a-rival-biotech-promises-a-better-show/

[E_L]

So Leering forecast peak worldwide sales of ~$1.7bn

[E_L]

Cowen $700 million